MIS416 Microparticles Modulate Immune Response for Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) are limited by adverse effects and lack of long-term efficacy, with no cure available, necessitating the development of alternative therapies that can effectively manage the disease with improved therapeutic profiles.
Innovation Solution
Administration of muramyl dipeptide cross-linked into microparticles (MIS416) as a standalone therapy or in combination with other active agents, which modulates the immune system by inducing anti-inflammatory cytokines and reducing leukocyte trafficking, thereby addressing the inflammatory and demyelinating aspects of MS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current MS treatments (immunomodulating and immunosuppressive strategies) are used, then inflammatory phase is reduced, but adverse effects occur and long-term efficacy is limited
Solution Approach 1:
The patent changes the therapeutic approach from immunosuppression to immunomodulation by using MDP microparticles that activate innate immune cells (dendritic cells, macrophages) to produce anti-inflammatory cytokines. This parameter change in mechanism of action provides sustained efficacy without the adverse effects associated with conventional immunosuppressive therapies
Solution Approach 2:
MDP microparticles serve as an intermediary that bridges innate and adaptive immunity. They activate innate immune cells which then modulate adaptive immune responses, providing a controlled immunomodulatory effect that reduces inflammation without the harsh side effects of direct immunosuppression
2Speed
If high doses of intravenous corticosteroids are administered, then acute relapses are relieved, but side effects such as osteoporosis and impaired memory occur
Solution Approach 1:
MDP microparticles are designed as biodegradable, transient immunomodulators that provide sustained effect through continuous activation of innate immune cells. Unlike corticosteroids which provide rapid but temporary relief with cumulative toxicity, MDP microparticles offer prolonged immunomodulation without accumulating adverse effects
Solution Approach 2:
The patent converts the harmful overactive immune response into a beneficial anti-inflammatory response by using MDP microparticles to activate innate immune cells to produce cytokines like IL-10 and TGF-β that actively suppress inflammation, rather than simply blocking immune function with corticosteroids
3Reliability
If frequent injections or IV infusions are required, then disease-modifying effects are achieved, but treatment complexity and patient burden increase
Solution Approach 1:
MDP microparticles provide sustained immunomodulation through continuous activation of innate immune cells, allowing for less frequent dosing compared to conventional therapies. The microparticles are processed slowly by the reticuloendothelial system, providing prolonged therapeutic effect that reduces treatment frequency while maintaining disease-modifying efficacy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is concerned with novel compositions and methods for the treatment of Multiple Sclerosis (MS) and in particular with immunostimulatory compositions comprising muramyl dipeptide microparticles in the treatment of MS.